Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.
Calvo T, Reina-Ortiz C, Giraldos D, Gascón M, Woods D, Asenjo J, Marco-Brualla J, Azaceta G, Izquierdo I, Palomera L, Sánchez-Martínez D, Marzo I, Naval J, Vilches C, Villalba M, Anel A. Calvo T, et al. Among authors: azaceta g. Sci Rep. 2020 Nov 10;10(1):19398. doi: 10.1038/s41598-020-76051-z. Sci Rep. 2020. PMID: 33173077 Free PMC article.
Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.
Sánchez-Martínez D, Azaceta G, Muntasell A, Aguiló N, Núñez D, Gálvez EM, Naval J, Anel A, Palomera L, Vilches C, Marzo I, Villalba M, Pardo J. Sánchez-Martínez D, et al. Among authors: azaceta g. Oncoimmunology. 2015 Jan 9;4(3):e991613. doi: 10.4161/2162402X.2014.991613. eCollection 2015 Mar. Oncoimmunology. 2015. PMID: 25949911 Free PMC article.
Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.
Sánchez-Martínez D, Lanuza PM, Gómez N, Muntasell A, Cisneros E, Moraru M, Azaceta G, Anel A, Martínez-Lostao L, Villalba M, Palomera L, Vilches C, García Marco JA, Pardo J. Sánchez-Martínez D, et al. Among authors: azaceta g. Front Immunol. 2016 Oct 27;7:454. doi: 10.3389/fimmu.2016.00454. eCollection 2016. Front Immunol. 2016. PMID: 27833611 Free PMC article.
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.
Reina-Ortiz C, Constantinides M, Fayd-Herbe-de-Maudave A, Présumey J, Hernandez J, Cartron G, Giraldos D, Díez R, Izquierdo I, Azaceta G, Palomera L, Marzo I, Naval J, Anel A, Villalba M. Reina-Ortiz C, et al. Among authors: azaceta g. Oncoimmunology. 2020 Dec 29;10(1):1853314. doi: 10.1080/2162402X.2020.1853314. Oncoimmunology. 2020. PMID: 33457074 Free PMC article.
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.
Serrano Del Valle A, Beltrán-Visiedo M, de Poo-Rodríguez V, Jiménez-Alduán N, Azaceta G, Díez R, Martínez-Lázaro B, Izquierdo I, Palomera L, Naval J, Anel A, Marzo I. Serrano Del Valle A, et al. Among authors: azaceta g. Oncoimmunology. 2022 Nov 1;11(1):2141973. doi: 10.1080/2162402X.2022.2141973. eCollection 2022. Oncoimmunology. 2022. PMID: 36338146 Free PMC article.
29 results